Sandra M E Geurts
Overview
Explore the profile of Sandra M E Geurts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tjan-Heijnen V, Lammers S, Geurts S, Vriens I, Swinkels A, Smorenburg C, et al.
EClinicalMedicine
. 2023 Mar;
58:101901.
PMID: 36992863
Background: The DATA study evaluated the use of two different durations of anastrozole in patients with hormone receptor-positive breast cancer who were disease-free after 2-3 years of tamoxifen. We hereby...
12.
Meegdes M, Geurts S, Erdkamp F, Dercksen M, Vriens B, Aaldering K, et al.
Lancet Reg Health Eur
. 2023 Mar;
26:100573.
PMID: 36895447
Background: This study aims to evaluate whether changes in therapeutic strategies have improved survival of patients diagnosed with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer (ABC) in...
13.
Ibragimova K, Geurts S, Meegdes M, Erdkamp F, Heijns J, Tol J, et al.
Breast Cancer Res Treat
. 2023 Jan;
198(2):239-251.
PMID: 36635428
Purpose: We assessed the systemic treatment choices and outcomes in patients diagnosed with human epidermal growth factor receptor-2-positive (HER2 +) advanced breast cancer (ABC), for the first four lines of...
14.
Brands M, Swinkels I, Aarts A, Verbeek A, Merkx M, Marres H, et al.
Head Neck
. 2022 Dec;
45(3):586-594.
PMID: 36565244
Background: The major goal of routine follow-up in oropharyngeal squamous cell carcinoma (OPSCC) patients is the asymptomatic detection of new disease in order to improve survival. This study evaluated the...
15.
Keymeulen K, Geurts S, Kooreman L, Duijm L, Engelen S, Vanwetswinkel S, et al.
Eur Radiol
. 2022 Sep;
33(3):2209-2217.
PMID: 36180645
Objectives: For patients with ductal carcinoma in situ (DCIS), data about the impact of breast MRI at primary diagnosis on the incidence and characteristics of contralateral breast cancers are scarce....
16.
Polee I, Hermans B, van der Zwan J, Bouwense S, Dercksen M, Eskens F, et al.
Eur J Cancer
. 2022 Jul;
172:252-263.
PMID: 35803176
Background: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) comprise a group of rare malignant tumours with heterogeneous behaviour. This study aimed to assess long-term survival and prognostic factors associated with survival, in...
17.
de Jong E, Mommers I, Sarasqueta A, van der Geest L, Heij L, de Hingh I, et al.
Acta Oncol
. 2022 Apr;
61(5):591-596.
PMID: 35382678
No abstract available.
18.
de Jong E, van der Geest L, Besselink M, Bouwense S, Buijsen J, Dejong C, et al.
HPB (Oxford)
. 2022 Feb;
24(9):1433-1442.
PMID: 35135724
Background: Periampullary adenocarcinoma consists of pancreatic adenocarcinoma (PDAC), distal cholangiocarcinoma (DC), ampullary cancer (AC), and duodenal adenocarcinoma (DA). The aim of this study was to assess treatment modalities and overall...
19.
Meegdes M, Ibragimova K, Lobbezoo D, Vriens I, Kooreman L, Erdkamp F, et al.
Breast Cancer Res Treat
. 2022 Jan;
192(2):331-342.
PMID: 35025003
Purpose: The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer, but can change during the...
20.
Geurts S, Aarts A, Verbeek A, Chen T, Broeders M, Duffy S
Epidemiol Health
. 2022 Jan;
44:e2022008.
PMID: 34990529
Objectives: The aim of this study was to provide an overview of published mathematical estimation approaches to quantify the duration of the preclinical detectable phase (PCDP) using data from cancer...